Autopsy report · NCT03710122

Vancomycin for Primary Sclerosing Cholangitis

“Funding terminated”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months before it started.
• Ran for about 5 years 2 months before it stopped.
• 102 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Elizabeth Carey

Sponsor type

University, hospital or other

Conditions

Primary Sclerosing Cholangitis

Interventions

Vancomycin; Placebo

Participants

102

Sites

4

Countries

United States

Trials that died the same way

• The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
  “Funding was terminated” (97% match in meaning)
• Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
  “Funding terminated by funding source.” (91% match in meaning)
• Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
  “Souces of funding have been terminated” (89% match in meaning)
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
  “Terminated due to insufficient funding” (88% match in meaning)
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
  “Terminated due to loss of funding” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.